(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

FEMAXEEN

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

FEMAXEEN

ST13

US500000079283723

Class

5

Filing

79283723

Registration

6230860

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

32

Latest update

12/30/2025

Trademark type

Word

Nice classes

5

Filing date

02/19/2020

Registration date

12/29/2020

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

12/29/2020

Last transaction

12/30/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

98

Owner location

MC

Examiner

DAVIS,MARC STEPHEN

Law office

N40

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

S. P. (pessoa física)
S.A.R.L. AXEEN PHARMA

Representatives

Clifford D. Hyra FRESH IP PLC

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical productsexcluding contraceptives and slimming productsfor the prevention and treatment of urinary incontinence and bladder control; dietetic foods for the treatment of incontinencefood supplements for human usewith the exception of contraceptives and slimming products; medical preparations for the prevention and treatment of urinary incontinence and bladder control for naturopathywith the exception of contraceptives and slimming productsparticularlyin the form of tabletscapsulesliquids

Publications

History of USPTO decisions and trademark events.

32 publications found

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

12/29/2025

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

11/28/2024

NREP

NEW REPRESENTATIVE AT IB RECEIVED

06/03/2023

NREP

NEW REPRESENTATIVE AT IB RECEIVED

06/05/2021

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

04/24/2021

FICS

FINAL DISPOSITION NOTICE SENT TO IB

04/01/2021

FIMP

FINAL DISPOSITION PROCESSED

04/01/2021

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

03/29/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

12/29/2020

GPNX

NOTIFICATION PROCESSED BY IB

10/18/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/13/2020

PUBO

PUBLISHED FOR OPPOSITION

10/13/2020

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

09/30/2020

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

09/30/2020

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

09/23/2020

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

09/08/2020

XAEC

EXAMINER'S AMENDMENT ENTERED

09/01/2020

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

09/01/2020

GNEA

EXAMINERS AMENDMENT E-MAILED

09/01/2020

CNEA

EXAMINERS AMENDMENT -WRITTEN

09/01/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/21/2020

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/21/2020

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

08/21/2020

RFNT

REFUSAL PROCESSED BY IB

07/18/2020

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

06/26/2020

RFRR

REFUSAL PROCESSED BY MPU

06/25/2020

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

05/22/2020

CNRT

NON-FINAL ACTION WRITTEN

05/21/2020

DOCK

ASSIGNED TO EXAMINER

05/07/2020

MAFR

APPLICATION FILING RECEIPT MAILED

04/28/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/24/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

04/23/2020

Continuous trademark protection

Get notified about every new filing that threatens FEMAXEEN or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.